PD-L1 pfeRNAs as blood-based predictors of treatment response of unresectable malignant pleural mesothelioma patients administered Durvalumab with cisplatin and pemetrexed as first-line therapy

Andrei Gurau(Johns Hopkins University), Yuping Mei(Johns Hopkins Hospital), Patrick M. Forde(Sidney Kimmel Comprehensive Cancer Center), James R. Eshleman(Johns Hopkins University), Joshua Choi(Kennedy Krieger Institute), Suguru Yamauchi(Johns Hopkins University), Peng Huang(Wildlife Conservation Society), Charles Conover Talbot(Johns Hopkins University), Malcolm V. Brock(Johns Hopkins University), Kristen Rodgers(Johns Hopkins University), Kaitlyn Ecoff(Johns Hopkins University), Valsamo Anagnostou(Johns Hopkins University)
Non-coding RNA Research
February 21, 2025
10.1016/j.ncrna.2025.02.003
Cited by 4

Related Papers

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
|Science|2017|6.6k
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
|Science|2008|4k
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
|New England Journal of Medicine|2018|2.1k
Genome-wide cell-free DNA fragmentation in patients with cancer
|Nature|2019|1.5k